JP2022166039A5 - - Google Patents

Download PDF

Info

Publication number
JP2022166039A5
JP2022166039A5 JP2022120558A JP2022120558A JP2022166039A5 JP 2022166039 A5 JP2022166039 A5 JP 2022166039A5 JP 2022120558 A JP2022120558 A JP 2022120558A JP 2022120558 A JP2022120558 A JP 2022120558A JP 2022166039 A5 JP2022166039 A5 JP 2022166039A5
Authority
JP
Japan
Prior art keywords
formulation
composition
product
kit described
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2022120558A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022166039A (ja
Filing date
Publication date
Priority claimed from JP2018530858A external-priority patent/JP2018537484A/ja
Application filed filed Critical
Publication of JP2022166039A publication Critical patent/JP2022166039A/ja
Publication of JP2022166039A5 publication Critical patent/JP2022166039A5/ja
Abandoned legal-status Critical Current

Links

JP2022120558A 2015-12-14 2022-07-28 肝内胆汁うっ滞および関連肝疾患の治療 Abandoned JP2022166039A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562266771P 2015-12-14 2015-12-14
US62/266,771 2015-12-14
JP2018530858A JP2018537484A (ja) 2015-12-14 2016-12-14 肝内胆汁うっ滞および関連肝疾患の治療
PCT/EP2016/080941 WO2017102816A1 (en) 2015-12-14 2016-12-14 Treatment of intrahepatic cholestasis and related liver diseases

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018530858A Division JP2018537484A (ja) 2015-12-14 2016-12-14 肝内胆汁うっ滞および関連肝疾患の治療

Publications (2)

Publication Number Publication Date
JP2022166039A JP2022166039A (ja) 2022-11-01
JP2022166039A5 true JP2022166039A5 (https=) 2022-12-22

Family

ID=57570064

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018530858A Pending JP2018537484A (ja) 2015-12-14 2016-12-14 肝内胆汁うっ滞および関連肝疾患の治療
JP2022120558A Abandoned JP2022166039A (ja) 2015-12-14 2022-07-28 肝内胆汁うっ滞および関連肝疾患の治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018530858A Pending JP2018537484A (ja) 2015-12-14 2016-12-14 肝内胆汁うっ滞および関連肝疾患の治療

Country Status (16)

Country Link
US (1) US20180369297A1 (https=)
EP (1) EP3389680B1 (https=)
JP (2) JP2018537484A (https=)
KR (1) KR20180094950A (https=)
CN (1) CN109069548A (https=)
AU (1) AU2016374365B2 (https=)
BR (1) BR112018012022A2 (https=)
CA (1) CA3008195A1 (https=)
CL (1) CL2018001548A1 (https=)
ES (1) ES2962302T3 (https=)
IL (1) IL259480B2 (https=)
MX (1) MX2018007227A (https=)
RU (1) RU2743405C2 (https=)
SG (1) SG11201804255QA (https=)
WO (1) WO2017102816A1 (https=)
ZA (1) ZA201804660B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
CA3212215A1 (en) 2012-11-23 2014-05-30 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP2967077A4 (en) 2013-03-15 2016-09-14 Seres Therapeutics Inc NETWORK-BASED MICROBIAL COMPOSITIONS AND METHOD
SG10201903823QA (en) 2014-10-31 2019-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
EP3668527A1 (en) * 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
CN111372596A (zh) 2017-08-30 2020-07-03 潘德勒姆治疗公司 用于治疗微生物组相关病症的方法和组合物
JP2021501185A (ja) 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法
CA3106315A1 (en) 2018-07-19 2020-01-23 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
EP3870691A4 (en) 2018-09-13 2022-09-07 Xbiome Inc. METHODS AND COMPOSITIONS FOR TREATING GASTROINTESTINAL AND INFLAMMATORY DISORDERS
CN112280720B (zh) * 2020-11-19 2021-07-13 山东龙昌动物保健品有限公司 一株多形拟杆菌gl-02及其与胆汁酸复配的复合菌剂与应用
US20250213600A1 (en) 2022-03-18 2025-07-03 Meiji Co., Ltd. Composition for controlling growth of bacteria in the intestinal tract and use thereof
GB2628547A (en) * 2023-03-27 2024-10-02 Univ Newcastle Probiotic and postbiotic compositions, products and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283225B1 (it) * 1996-03-11 1998-04-16 Renata Maria Anna Ve Cavaliere Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle
WO2000071138A2 (en) * 1999-05-25 2000-11-30 Gregor Reid Oral administration of lactobacillus for the maintenance of health in women
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
CA2642431A1 (en) * 2006-02-15 2007-08-23 Nestec S.A. Use of bifidobacterium longum for the prevention and treatment of inflammation
US20120128633A1 (en) * 2009-04-30 2012-05-24 Campagnie Gervaise Donone Use of collinsella aerofaciens for reducing bloating
CN102539791A (zh) * 2012-01-09 2012-07-04 宁波天康生物科技有限公司 总胆汁酸的定量测定及测定试剂盒
AU2014331610B2 (en) * 2013-10-03 2019-11-07 Trustees Of The University Of Pennsylvania Compositions comprising a defined microbiome and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2022166039A5 (https=)
JP2023164986A5 (https=)
JP2023113641A5 (https=)
JP2023171775A5 (https=)
JP2022184985A5 (https=)
JP2023103258A5 (https=)
JP2024156852A5 (https=)
JP2024133471A5 (https=)
JP2026012786A5 (https=)
JP2024037765A5 (https=)
JP2023113681A5 (https=)
JP2023145572A5 (https=)
JP2025023938A5 (https=)
JP2023181322A5 (https=)
JP2023153863A5 (https=)
JP2024045126A5 (https=)
JP2025106258A5 (https=)
JP2023103231A5 (https=)
JP2025118771A5 (https=)
JP2024156705A5 (https=)
JP2023154065A5 (https=)
JP2023093656A5 (https=)
JPWO2022202973A5 (https=)
JP2023139025A5 (https=)
JP2025038009A5 (https=)